{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:42:18Z","timestamp":1793313738723,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.lungcan.2025.108532","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:14:27Z","timestamp":1744197267000},"page":"108532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Efficacy and safety of targeted therapy combined with anti-angiogenesis treatment in brain metastases of non-small cell lung cancer: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2348-4104","authenticated-orcid":false,"given":"Yin","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaohua","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lungcan.2025.108532_b0005","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1016\/j.cllc.2018.01.007","article-title":"Non-small-cell lung cancer with brain metastasis at presentation","volume":"19","author":"Waqar","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"19","key":"10.1016\/j.lungcan.2025.108532_b0010","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1002\/cncr.33085","article-title":"Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non-small cell lung cancer brain metastases","volume":"126","author":"Steindl","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2025.108532_b0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ctrv.2016.03.009","article-title":"The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer","volume":"45","author":"Peters","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108532_b0020","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1200\/JOP.19.00357","article-title":"Management of brain metastases in non-small-cell lung cancer","volume":"15","author":"Ernani","year":"2019","journal-title":"J. Oncol. Pract."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108532_b0025","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11864-013-0258-0","article-title":"Treatment of brain metastases in lung cancer: strategies to avoid\/reduce late complications of whole brain radiation therapy","volume":"14","author":"Shaw","year":"2013","journal-title":"Curr. Treat. Options Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108532_b0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1023\/B:NEON.0000014518.16481.7e","article-title":"Delayed radiation toxicity after focal or whole brain radiotherapy for low-grade glioma","volume":"66","author":"Swennen","year":"2004","journal-title":"J. Neurooncol."},{"issue":"23","key":"10.1016\/j.lungcan.2025.108532_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315056","article-title":"Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance","volume":"23","author":"Wu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108532_b0040","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12272-022-01382-6","article-title":"Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer","volume":"45","author":"Choi","year":"2022","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.lungcan.2025.108532_b0045","article-title":"The role of anti-angiogenesis in the treatment landscape of non-small cell lung cancer - new combinational approaches and strategies of neovessel inhibition","volume":"8","author":"Daum","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.lungcan.2025.108532_b0050","first-page":"259","article-title":"Bevacizumab in the treatment of NSCLC: patient selection and perspectives","volume":"8","author":"Russo","year":"2017","journal-title":"Lung Cancer (Auckl)."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108532_b0055","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","article-title":"Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study","volume":"39","author":"Zhou","year":"2021","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108532_b0060","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11864-019-0617-6","article-title":"The role of angiogenesis inhibitors in the era of immune checkpoint inhibitors and targeted therapy in metastatic non-small cell lung cancer","volume":"20","author":"Perdrizet","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108532_b0065","doi-asserted-by":"crossref","first-page":"e6073","DOI":"10.1590\/1414-431x20176073","article-title":"Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer","volume":"51","author":"Yang","year":"2017","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"121","key":"10.1016\/j.lungcan.2025.108532_b0070","first-page":"98","article-title":"EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases","volume":"2019","author":"Jiang","year":"1990","journal-title":"Eur. J. Cancer (Oxford, England)"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108532_b0075","first-page":"618","article-title":"Effect of endostar combined with gefitinib on multiple brain metastases of non-small cell lung cancer after whole brain radiotherapy","volume":"14","author":"Li","year":"2021","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108532_b0080","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","article-title":"Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study","volume":"39","author":"Zhou","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108532_b0085","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1038\/s41598-022-08449-w","article-title":"The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis","volume":"12","author":"Chiu","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108532_b0090","article-title":"Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108532_b0095","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2967\/jnumed.116.187047","article-title":"Influence of bevacizumab on blood-brain barrier permeability and O-(2-(18)F-fluoroethyl)-l-tyrosine uptake in rat gliomas","volume":"58","author":"Stegmayr","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108532_b0100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072606","article-title":"The epigenetic profile of tumor endothelial cells. Effects of combined therapy with antiangiogenic and epigenetic drugs on cancer progression","volume":"21","author":"Ciesielski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108532_b0105","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1515\/med-2020-0192","article-title":"Bevacizumab for non-small cell lung cancer patients with brain metastasis: a meta-analysis","volume":"15","author":"Liang","year":"2020","journal-title":"Open Med. (Wars)."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108532_b0110","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.18632\/oncotarget.6184","article-title":"Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis","volume":"7","author":"Tang","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108532_b0115","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4143\/crt.2021.671","article-title":"The clinical outcomes of different first-line EGFR-TKIs plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma","volume":"54","author":"Huang","year":"2022","journal-title":"Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108532_b0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.21037\/cco.2016.11.02","article-title":"A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation","volume":"5","author":"Hirano","year":"2016","journal-title":"Chin. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:28:56Z","timestamp":1777782536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225004246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":24,"alternative-id":["S0169500225004246"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108532","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of targeted therapy combined with anti-angiogenesis treatment in brain metastases of non-small cell lung cancer: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108532","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108532"}}